Document Detail


Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age.
MedLine Citation:
PMID:  20571428     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: In patients with diabetes mellitus type 2 and arterial hypertension, the control of systolic and diastolic blood pressure is essential to reduce the risk of adverse events. The present study investigates the effect of treatment with the third-generation beta-blocker nebivolol, in female and male patients of different ages.
METHODS: Five thousand thirty-one male and female patients with mild to moderate hypertension and type 2 diabetes were treated with a daily dose of 5-mg nebivolol for 12 weeks. Before and after therapy, each patient's blood pressure, heart rate, and body weight were measured and blood samples were obtained to study metabolic parameters.
RESULTS: Nebivolol reduced systolic blood pressure, in both sexes, to a similar extent. In regard to age, the most significant reduction in blood pressure over the 12-week treatment period was observed in the group of patients below the age of 40. With advancing age, there was a decline in the reduction of systolic blood pressure induced by nebivolol. This effect was more evident among the decennial age groups in respect to diastolic blood pressure. In addition, we found weight reduction to be age dependent. Body weight was significantly more reduced in men compared with women.
CONCLUSIONS: Nebivolol is effective in treating patients with diabetes suffering from high blood pressure and metabolic syndrome. The significantly decreased effect on blood pressure found in elderly patients may be attributed to increased endothelial dysfunction with advancing age.
Authors:
Dennis Ladage; Christian Reidenbach; Eva Rieckeheer; Christine Graf; Robert H G Schwinger; Klara Brixius
Related Documents :
20071978 - Validation of panasonic ew3106 and ew3109 devices for blood pressure measurement accord...
2338698 - Effects of nitrendipine and atenolol on blood pressure and intracellular sodium in hype...
333958 - Daily relaxation response breaks in a working population: ii. effects on blood pressure.
19821418 - Blood pressure lowering efficacy of coenzyme q10 for primary hypertension.
1527718 - Purinergic vasoconstrictor component revealed by moderate cooling in the isolated mesen...
17307988 - The quantitative relationship between longitudinal and radial function in left, right, ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  56     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  275-81     Citation Subset:  IM    
Affiliation:
Department of Molecular and Cellular Sport Medicine, Institute of Cardiology and Sport Medicine, German Sport University Cologne, Cologne, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel highly selective adenosine A1 receptor agonist VCP28 reduces ischemia injury in a cardiac ce...
Next Document:  Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.